Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an LP.8.1 angepassten COVID-19-Impfstoff in der Europäischen Union
Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an LP.8.1 angepassten COVID-19-Impfstoff in der Europäischen Union
  • Daten zeigten, dass der an LP.8.1 angepasste COVID-19-Impfstoff verglichen mit den COVID-19-Impfstoffformulierungen 2024-2025 eine verbesserte Immunantwort gegen derzeit vorherrschende und neu
Unitedhealth Stock: Justice Department Probe Rattles Investors
Unitedhealth Stock: Justice Department Probe Rattles Investors

The healthcare giant UnitedHealth confirmed Thursday it is cooperating with both criminal and civil investigations by the U.S. Justice Department regarding its Medicare Advantage business practices

Unitedhealth Stock: Justice Department Probe Rattles Investors
Unitedhealth Stock: Justice Department Probe Rattles Investors

The healthcare giant UnitedHealth confirmed Thursday it is cooperating with both criminal and civil investigations by the U.S. Justice Department regarding its Medicare Advantage business practices

Merck Aktie: Macht der neue CEO alles anders?
Merck Aktie: Macht der neue CEO alles anders?

Der DAX-Konzern steht vor einem Paradigmenwechsel: Kai Beckmann, derzeit Leiter der Electronics-Sparte, soll laut…

Der Beitrag Merck Aktie: Macht der neue CEO alles anders? erschien zuerst auf kapit

Abivax Stock: $650M Capital Raise Extends Runway
Abivax Stock: $650M Capital Raise Extends Runway

Abivax has successfully completed its capital raise of $650 million (€554 million) through the issuance of 10.156 million American Depositary Shares priced at $64 each. The offering, which concluded

Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound

Today’s stock market focus is centered on one single sector: technology stocks.

The excitement around artificial intelligence (AI) has led to most attention—and capital–being concentrated in one

Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound

Today’s stock market focus is centered on one single sector: technology stocks.

The excitement around artificial intelligence (AI) has led to most attention—and capital–being concentrated in one

Intuitive Surgical Stock: Profit Surge Raises Valuation Questions
Intuitive Surgical Stock: Profit Surge Raises Valuation Questions

Intuitive Surgical delivered impressive second-quarter 2025 results that exceeded analyst expectations, with revenue jumping 21% to $2.44 billion and earnings per share reaching $2.19, significantly

Intuitive Surgical Stock: Profit Surge Raises Valuation Questions
Intuitive Surgical Stock: Profit Surge Raises Valuation Questions

Intuitive Surgical delivered impressive second-quarter 2025 results that exceeded analyst expectations, with revenue jumping 21% to $2.44 billion and earnings per share reaching $2.19, significantly

Intuitive Surgical Stock: Profit Surge Raises Valuation Questions
Intuitive Surgical Stock: Profit Surge Raises Valuation Questions

Intuitive Surgical delivered impressive second-quarter 2025 results that exceeded analyst expectations, with revenue jumping 21% to $2.44 billion and earnings per share reaching $2.19, significantly

Viking Therapeutics Aktie: Entscheidungstag!
Viking Therapeutics Aktie: Entscheidungstag!

Die Börse hält heute den Atem an: Viking Therapeutics steht vor einem entscheidenden Bericht.…

Der Beitrag Viking Therapeutics Aktie: Entscheidungstag! erschien zuerst auf kapitalmarktexperten.de.

Q

Thermo Fisher Stock: Strong Q2 Results Spark Rally
Thermo Fisher Stock: Strong Q2 Results Spark Rally

Thermo Fisher Scientific has exceeded Wall Street expectations in its second quarter, triggering a dramatic 12 percent stock surge to $479.02. The laboratory equipment supplier reported adjusted

Roche Stock: Dual Approvals Boost Growth Prospects
Roche Stock: Dual Approvals Boost Growth Prospects

The Swiss pharmaceutical giant Roche secured two significant regulatory victories, potentially strengthening its market position across key therapeutic areas. The European Commission granted

Roche Stock: Dual Approvals Boost Growth Prospects
Roche Stock: Dual Approvals Boost Growth Prospects

The Swiss pharmaceutical giant Roche secured two significant regulatory victories, potentially strengthening its market position across key therapeutic areas. The European Commission granted

Lonza erzielt starkes Ergebnis im ersten Halbjahr 2025 und erhöht Umsatz- und Margenprognose für das CDMO-Geschäft im Gesamtjahr 2025
Lonza erzielt starkes Ergebnis im ersten Halbjahr 2025 und erhöht Umsatz- und Margenprognose für das CDMO-Geschäft im Gesamtjahr 2025
Lonza erzielt starkes Ergebnis im ersten Halbjahr 2025 und erhöht Umsatz- und Margenprognose für das CDMO-Geschäft im Gesamtjahr 2025
Roche Stock: Capital Structure Overhaul Eliminates Paper Relics
Roche Stock: Capital Structure Overhaul Eliminates Paper Relics

The Swiss pharmaceutical giant Roche is planning a fundamental restructuring of its capital structure, marking a significant departure from outdated financial instruments. The company's board will

Roche Stock: Capital Structure Overhaul Eliminates Paper Relics
Roche Stock: Capital Structure Overhaul Eliminates Paper Relics

The Swiss pharmaceutical giant Roche is planning a fundamental restructuring of its capital structure, marking a significant departure from outdated financial instruments. The company's board will

EQS-News: Sartorius weiter auf Wachstumskurs, Ertrag steigt deutlich überproportional: https://www.sharewise.com/rails/active_storage/blobs/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBhQT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--b12b7dfadf2c58d9e1a19e072122a740f7f20d88/Sartorius.svg?locale=us
EQS-News: Sartorius weiter auf Wachstumskurs, Ertrag steigt deutlich überproportional
EQS-News: Sartorius weiter auf Wachstumskurs, Ertrag steigt deutlich überproportional
EQS-News: Sartorius weiter auf Wachstumskurs, Ertrag steigt deutlich überproportional: https://www.sharewise.com/rails/active_storage/blobs/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBhQT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--b12b7dfadf2c58d9e1a19e072122a740f7f20d88/Sartorius.svg?locale=us
EQS-News: Sartorius weiter auf Wachstumskurs, Ertrag steigt deutlich überproportional
EQS-News: Sartorius weiter auf Wachstumskurs, Ertrag steigt deutlich überproportional
Biogen Stock: $2 Billion US Expansion Signals Growth
Biogen Stock: $2 Billion US Expansion Signals Growth

Biogen is intensifying its manufacturing footprint with a $2 billion investment in North Carolina's Research Triangle Park, strategically timed amid potential import tariff threats of up to 200

Biogen Stock: $2 Billion US Expansion Signals Growth
Biogen Stock: $2 Billion US Expansion Signals Growth

Biogen is intensifying its manufacturing footprint with a $2 billion investment in North Carolina's Research Triangle Park, strategically timed amid potential import tariff threats of up to 200

Biogen Stock: $2 Billion US Expansion Signals Growth
Biogen Stock: $2 Billion US Expansion Signals Growth

Biogen is intensifying its manufacturing footprint with a $2 billion investment in North Carolina's Research Triangle Park, strategically timed amid potential import tariff threats of up to 200

Roche Stock: COPD Drug Failure Deals Pipeline Blow
Roche Stock: COPD Drug Failure Deals Pipeline Blow

Pharmaceutical giant Roche faces significant setbacks after its promising COPD drug candidate Astegolimab failed to meet primary endpoints in the crucial Phase III ARNASA study. The experimental

Roche Stock: COPD Drug Failure Deals Pipeline Blow
Roche Stock: COPD Drug Failure Deals Pipeline Blow

Pharmaceutical giant Roche faces significant setbacks after its promising COPD drug candidate Astegolimab failed to meet primary endpoints in the crucial Phase III ARNASA study. The experimental

3 Bullish Biotech Stocks With Explosive Growth Trends
3 Bullish Biotech Stocks With Explosive Growth Trends

Investing in biotechnology stocks is similar to the drug development process itself. That is, investors frequently experience long periods of nothing much happening, interrupted by periods of